



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/425992/2011

European Medicines Agency decision P/137/2011

of 10 June 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701) (EMA-001057-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/137/2011

of 10 June 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701) (EMA-001057-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by FerroKin BioSciences Ltd on 06 September 2010 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 April 2011, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for (S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701), powder for oral solution, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for (S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701), powder for oral solution, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for (S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701), powder for oral solution, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to FerroKin BioSciences Ltd, 150 Waterloo Road, SE1 8SB - London, United Kingdom.

Done at London, 10 June 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/200963/2011

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001057-PIP01-10

Scope of the application

Active substance(s):

(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701)

Condition(s):

Treatment of chronic iron overload requiring chelation therapy

Pharmaceutical form(s):

Powder for oral solution

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

FerroKin BioSciences Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, FerroKin BioSciences Ltd submitted for agreement to the European Medicines Agency on 06 September 2010 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 13 October 2010.

Supplementary information was provided by the applicant on 4 February 2011. The applicant proposed modifications to the paediatric investigation plan.

A meeting with the Paediatric Committee took place on 19 April 2011.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 20 April 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of chronic iron overload requiring chelation therapy

The waiver applies to:

- All subsets of the paediatric population from birth to less than 2 years of age;
- for powder for oral solution, oral use;
- for hard capsule, oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of chronic iron overload requiring chelation therapy

2.1.1. Indication(s) targeted by the PIP

Treatment of transfusional iron overload.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for oral solution

Capsule, hard

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Measure 1: Development of a powder for oral solution formulation for administering adequate doses to children down to 2 years of age.
Non-clinical	1	Study 2: Juvenile toxicology and toxicokinetic study in rat.
Clinical	3	Study 3: Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Activity and Tolerability of FBS0701 in a Paediatric Population with Transfusional Iron Overload. Study 4: Open Label, Multi-Center, Single-Dose Pharmacokinetics and Pharmaceutical Interchangeability Study of Two Formulations of FBS0701 and Multiple Dose Study of the Safety, Activity and Tolerability of FBS0701 in a Paediatric Population with Transfusional Iron Overload. Study 5: Comparator-Controlled Study of the Safety and Efficacy of FBS0701 in the Treatment of Adults and Children with Transfusional Iron Overload with Open Long-Term Safety Follow up.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2016
Deferral for one or more studies contained in the paediatric investigation plan:	Yes